Dr James Cornwall joins AUM Biosciences’ Board of Advisors
AUM Biosciences (AUM), a Singapore-based company officially announced today that Dr James Cornwall has joined its Board of Advisors. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical need in Asia.
About Dr James Cornwall
Dr James Cornwall is a seasoned business and scientific professional with more than 25 years experience in the pharmaceutical industry. He has broad-based experience and proven ability in operations, sales, deal execution and alliance development which spans Europe, USA and Asia.
James played a key role as a senior team member of small team at Quintiles responsible for the commitment of over $2.7bn investments in the pharmaceutical space over 10 years. He is highly recognised for creating a series of transformational business relationships with pharmaceuticals, biotech and their investors, including – joint ventures, pharmaceuticals spin-outs, direct equity investments, project financing and limited partner VC fund investments.
James was also instrumental in the $30m joint venture transaction between Quintiles and Samsung and served on the Board of Directors at Samsung Biologics, the entity created in the transaction, for 3 years.
He has created and led governance structures and operational delivery models for clinical and consulting relationships with key Korean customers at Quintiles and has served on its Asia Markets Leadership Team and Asia Pacific Regional Board. He also led ‘EBio’ biotech investment model in EU and US while at Quintiles where he managed 8 biotech equity investments and relationships.
“After living and working in both the West and Asia, it’s clear to me that companies like AUM are well-positioned to couple the scientific and medical excellence emerging from Asia with the deep commercial knowledge and wide reach of established Western pharmaceutical companies. Building these links and benefiting from the ‘best of both worlds’ will be to the benefit of oncology patients worldwide, especially those in underserved markets,” says Dr James Cornwall, Board Member, AUM Biosciences.
James is currently the Chief Business Officer of Nuvelution Pharma Inc where he has led and managed 2 deals to date with approximately $200M under management. His previous roles include VP of Corporate Development, Quintiles Asia Pacific, Boston MA, and UK. He has also held research positions in Glaxo Group Research UK and University of Bristol.
James holds a BSc in Pharmacology and a PhD in Neuropharmacology from the University Of Bristol and has completed postgraduate training in Executive Leadership from the University of North Carolina Kenan Flagler Business School.
AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.
AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need. For more information, please visit www.aumbiosciences.com or email firstname.lastname@example.org.